- Home
- MBC vs CLDX Comparison
MBC vs CLDX Comparison
Compare MBC & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- CLDX
- Stock Information
- Founded
- MBC 1954
- CLDX N/A
- Country
- MBC United States
- CLDX United States
- Employees
- MBC N/A
- CLDX N/A
- Industry
- MBC Agricultural Chemicals
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MBC Industrials
- CLDX Health Care
- Exchange
- MBC Nasdaq
- CLDX Nasdaq
- Market Cap
- MBC 1.6B
- CLDX 1.4B
- IPO Year
- MBC N/A
- CLDX 2008
- Fundamental
- Price
- MBC $12.72
- CLDX $22.08
- Analyst Decision
- MBC Strong Buy
- CLDX Strong Buy
- Analyst Count
- MBC 1
- CLDX 9
- Target Price
- MBC $15.00
- CLDX $46.13
- AVG Volume (30 Days)
- MBC 1.9M
- CLDX 1.5M
- Earning Date
- MBC 08-06-2025
- CLDX 08-07-2025
- Dividend Yield
- MBC N/A
- CLDX N/A
- EPS Growth
- MBC N/A
- CLDX N/A
- EPS
- MBC 0.72
- CLDX N/A
- Revenue
- MBC $2,777,000,000.00
- CLDX $5,790,000.00
- Revenue This Year
- MBC $0.13
- CLDX N/A
- Revenue Next Year
- MBC $3.29
- CLDX N/A
- P/E Ratio
- MBC $17.60
- CLDX N/A
- Revenue Growth
- MBC 4.05
- CLDX N/A
- 52 Week Low
- MBC $9.63
- CLDX $14.40
- 52 Week High
- MBC $20.67
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- MBC 55.15
- CLDX 47.99
- Support Level
- MBC $12.01
- CLDX $21.34
- Resistance Level
- MBC $13.36
- CLDX $23.27
- Average True Range (ATR)
- MBC 0.50
- CLDX 1.54
- MACD
- MBC -0.00
- CLDX -0.15
- Stochastic Oscillator
- MBC 58.84
- CLDX 33.75
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.